<DOC>
	<DOC>NCT01253629</DOC>
	<brief_summary>This Phase IIb study is designed to assess whether 3 doses of AFQ056 are safe and effective in treating the behavioral symptoms of Fragile X Syndrome.</brief_summary>
	<brief_title>Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Patients with Fragile X Syndrome, who are at least moderately ill based on a Clinical Global Impression Severity score of at least 4 and have qualifying scores on the ABCC and IQ test at Visit 1 Advanced, severe or unstable disease that may interfere with the study outcome evaluations Cancer within the past 5 years, other than localized skin cancer Current treatment with more than two psychoactive medications, excluding antiepileptics History of severe selfinjurious behavior Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Fragile X Syndrome</keyword>
	<keyword>Martin-Bell Syndrome</keyword>
	<keyword>Genetic Diseases</keyword>
	<keyword>X-Linked</keyword>
</DOC>